Sleep is the most commonly cited reason people use medical cannabis. An estimated 70 million Americans have chronic sleep problems, and many have turned to cannabis after finding conventional sleep aids inadequate or intolerable. But what does the science actually say? The answer is nuanced — cannabis can genuinely help with sleep in specific contexts, but it also carries risks that are often underappreciated.
Sleep is not a uniform state — it cycles through distinct stages with different physiological functions. Understanding how cannabis affects each stage is essential for evaluating its therapeutic potential and risks.
THC reduces sleep onset latency — the time it takes to fall asleep. This is one of the most consistent findings in cannabis sleep research. Even low doses (5–10mg THC) can reduce sleep onset by 15–30 minutes in people with insomnia. CBD at higher doses (160mg) has also shown sleep-onset benefits in clinical studies.
THC increases time spent in slow wave sleep (SWS) — the deepest, most physically restorative sleep stage. This is associated with improved physical recovery, immune function, and growth hormone release. This effect is most pronounced in the first half of the night.
THC suppresses REM sleep — the stage associated with dreaming, emotional processing, and memory consolidation. This is why THC reduces nightmares in PTSD patients (a therapeutic benefit) but may impair emotional memory processing with long-term use. REM rebound — vivid, intense dreams — occurs when stopping cannabis after regular use.
Acute cannabis use generally increases total sleep time. However, tolerance develops to this effect within weeks of regular use, and chronic users often report worse sleep than non-users — suggesting long-term use may impair sleep quality despite short-term benefits.
CBD and THC affect sleep through fundamentally different mechanisms, and their optimal use cases differ significantly.
THC promotes sleep primarily through direct CB1 receptor activation in the brainstem and hypothalamus, reducing arousal and promoting sedation. It's most effective for sleep-onset insomnia and nightmare-related sleep disruption. The sedating effect is dose-dependent — low doses (2.5–5mg) can be mildly stimulating in some people, while higher doses (10–20mg) are reliably sedating.
CBD works differently — it doesn't directly sedate but rather reduces the anxiety, pain, and hyperarousal that prevent sleep. At lower doses (15–25mg), CBD may actually be mildly alerting. At higher doses (75–160mg), it has shown sedating effects in clinical studies. CBD's sleep benefits are most pronounced in people whose insomnia is secondary to anxiety, pain, or PTSD — it addresses the underlying cause rather than forcing sedation.
A 2017 systematic review in Current Psychiatry Reports examined 34 studies on cannabis and sleep. Key findings:
5–10mg THC oral capsule or 2.5–5mg sublingual, 30–60 min before bed. Start at the lowest effective dose. Consider 1:1 CBD:THC ratio to reduce next-day grogginess.
Oral/edible formulations preferred — longer duration (6–8 hours) vs sublingual (4–6 hours). 5–10mg THC in capsule form at bedtime. Extended-release formulations where available.
5–10mg THC 30 min before bed. This is the most evidence-supported use case. Nabilone (synthetic THC) 0.5–3mg has the strongest RCT evidence for PTSD nightmares specifically.
CBD-dominant: 25–75mg CBD sublingual or oral, 1 hour before bed. Address daytime anxiety with 15–25mg CBD twice daily. THC may worsen anxiety in some patients — start with CBD-only.
One of the most important — and underappreciated — aspects of cannabis for sleep is tolerance. The sleep-promoting effects of THC diminish significantly within 3–7 weeks of nightly use. Many patients find themselves needing progressively higher doses to achieve the same effect, eventually reaching doses that cause next-day impairment.
Strategies to manage tolerance include: intermittent use (5 nights on, 2 nights off), "tolerance breaks" of 1–2 weeks every 2–3 months, rotating between THC and CBD-dominant products, and using cannabis as a bridge while addressing underlying sleep issues with CBT-I.
Cannabis can be a genuinely effective short-term sleep aid, particularly for sleep-onset insomnia, PTSD nightmares, and sleep disruption secondary to pain or anxiety. The evidence for long-term nightly use is less favorable — tolerance, REM suppression, and withdrawal insomnia are real concerns. The most evidence-supported approach is intermittent use as an adjunct to addressing underlying sleep issues, not as a permanent nightly sedative. CBT-I remains the gold-standard treatment for chronic insomnia and should be considered alongside or before cannabis therapy.